Might have to work harder for a re-rating
09/01/26 -"Hikma, over the years, has struggled to create shareholder wealth, perhaps because of its inability (until now) to develop biosimilars on its own. The share price is around the same levels as it was ..."
Pages
50
Language
English
Published on
09/01/26
You may also be interested by these reports :
15/01/26
In late-2024, when we last teased the story of DiaSorin (BUY; Italy), a family-owned in-vitro diagnostic company specialising in immunodiagnostics ...
09/01/26
Hikma, over the years, has struggled to create shareholder wealth, perhaps because of its inability (until now) to develop biosimilars on its own. ...
31/12/25
Keeping in mind the underwhelming late-stage results of the immunology drug, amlitelimab, and a few other R&D setbacks in recent years, we have ...
30/12/25
Over the last three years, GSK’s earnings have exceeded the market’s expectations on most occasions. Moreover, the firm’s R&D efforts have yielded ...